Disease-modifying therapies in relapsing-remitting multiple sclerosis.

Neuropsychiatr Dis Treat · 2010 · PMC2938285 · PMID 20856600

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

26 Methotrexate The only study of methotrexate in progressive MS revealed a nonsignificant trend in sustained reduction of disease progression on the Expanded Disability Status Scale and number of relapses in favor of methotrexate.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.